EU News 03 Feb 2012
The European Union has some of the world's best research facilities and most accomplished researchers. Harnessing their full potential will help turn novel ideas into jobs, green growth and social progress. To facilitate this, the European Commission finances, either wholly or partially, a wide range of individual research and technology development projects. Details about many of these can be found on the Community Research and Development Information Service (CORDIS) - the primary information source for EU-funded projects.  A new Projects Service, launched on 16 January 2012, will...
Final results were presented from the AIM-HIGH study, a National Heart, Lung and Blood Institute (NHLBI) study. The study was designed to test whether raising HDL "good" cholesterol by adding Niaspan to simvastatin would provide an additional 25 percent reduction in cardiovascular outcomes in patients with established cardiovascular...
Industry News
Even though the use of device therapies for the treatment of heart failure, heart rhythm disturbances and atrial fibrillation has increased enormously in Europe in recent years, there still remains a fear that economic policy, and not just evidence-based therapeutic benefit, will determine access to treatments, especially at this time of financial...
Association News
Dr. Max Harry Weil, called the father of the critical care movement, died of prostate cancer at his home at age 84. The founder of the Weil Institute of Critical Care, he is credited with developing the first ICUs and introducing computerised patient monitors. "The things that we are doing right now are all because of him," said Dr....
Leader Portraits, Management, Research
The European Society of Cardiology (ESC) welcomes an “intriguing” study, published today in the Journal of the American College of Cardiology, featuring a completely novel approach for improving endothelial function in heart failure¹.  In the “hypothesis generating” study, ursodeoxycholic acid (UDCA)...
Research
The European Union has some of the world's best research facilities and most accomplished researchers. Harnessing their full potential will help turn novel ideas into jobs, green growth and social progress. To facilitate this, the European Commission finances, either wholly or partially, a wide range of individual research and technology...
EU News
Measuring the levels of a natural body chemical may allow doctors to reduce the duration of antibiotic use and improve the health outcomes of critically ill patients. "Infection is a common and expensive complication of critical illness and we're trying to find ways to improve the outcomes of sick, elderly patients and, at the same time...
Management, National, Research
Conference News 19 Jan 2012
Innovative healthcare IT and medical technology solutions are one step closer to winning the coveted IT @ 2012 trophy and cash prize at the IT @ Networking Awards 2012.   Willy Heuschen, Secretary General of the European Association of Hospital Managers officially opened the event, welcoming contestants and delegates. Heuschen highlighted the increasing importance and relevance of healthcare IT and the great opportunity the IT @ Networking Awards is for decision-makers to learn about these solutions; to have access to their developers and users; and to ask questions and judge the...

Running Out Of Treatments: The Problem Superbugs Resistant To Everything

"Doctors in many countries have gone back to using old antibiotics that were abandoned 20 years ago because their toxic side effects were so frequent and so bad", says Professor Matthew Falagas from the Alfa Institute of Biomedical Sciences in Athens, Greece and Tufts University School of Medicine, Boston, Massachusetts. "But superbugs like Acinetobacter have challenged doctors all over the world by now becoming resistant to these older and considered more dangerous medicines."

"Even colistin, a polymyxin type antibiotic discovered 60 years ago, has recently been used as a salvage remedy to treat patients with Acinetobacter infections", says Professor Falagas. "And it was successful for a while, but now it occasionally fails due to recent extensive use that has caused the bacteria to become resistant, leading to problem superbugs which are pan-drug resistant, in other words resistant to all available antibiotics."

The Greek researchers have also shown in new data analyses that Acinetobacter is a more serious threat than previously thought -- it doesn't just cause severe infections, it kills many more patients than doctors had realised. Acinetobacter can cause pneumonia, skin and wound infections and in some cases meningitis.

The scientists have also identified a whole range of drug resistant strategies being used by the bacteria, including the production of compounds which can inactivate the drug treatments, cell pumps that can bail out the drug molecules from inside bacterial cells making them ineffective, and mutating the drug target sites making the drug molecules miss or fail to latch onto the specific regions of the bacterial cells that they were aiming for.

"There have already been severe problems with critically ill patients due to Acinetobacter baumannii infections in various countries", says Matthew Falagas. "In some cases we have simply run out of treatments and we could be facing a pandemic with important public health implications".

Adapted from materials provided by Society for General Microbiology, via EurekAlert!, a service of AAAS.

www.sciencedaily.com

Mon, 2008-04-07 17:12